Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT06096974 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Start date: October 2023
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.

NCT ID: NCT06094556 Recruiting - Clinical trials for Advanced Solid Tumors

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

Start date: December 25, 2023
Phase: Phase 1
Study type: Interventional

This is an open, multi-center, dose-escalation/dose-expansion/efficacy expansion phase I clinical study to evaluate the tolerability, safety, PK, and immunogenicity of SHR-1826 in patients with advanced malignant solid tumors, and to preliminatively observe its antitumor efficacy. The whole study was divided into three stages: dose increment, dose extension and therapeutic effect extension.

NCT ID: NCT06092268 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Start date: October 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in combination with other antitumor therapies in patients with advanced solid tumors.

NCT ID: NCT06082570 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients

Start date: October 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-labeled, single-arm, multiple-dose escalation and single-dose expansion clinical study of cell therapy to observe and evaluate the safety and efficacy of c610 injection in the treatment of patients with advanced solid tumors.

NCT ID: NCT06076291 Recruiting - Clinical trials for Advanced Solid Tumors

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors

CSG-1827-101
Start date: September 27, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid Tumors, refractory or resistant to standard therapy, or without available standard or curative therapy.

NCT ID: NCT06047431 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of QL1706H in Patients With Advanced Solid Tumors

Start date: October 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase Ⅰ study of QL1706H in patients with advanced solid tumors. The study will evaluate the pharmacokenetics, safety, tolerability and preliminary efficacy of QL1706H.

NCT ID: NCT06040541 Recruiting - Clinical trials for Advanced Solid Tumors

Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

Start date: September 7, 2023
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors.

NCT ID: NCT06039384 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Start date: December 28, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.

NCT ID: NCT06028373 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Start date: December 8, 2023
Phase: Phase 1
Study type: Interventional

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D(Refered Phase II dose) of ATG-031.

NCT ID: NCT06026501 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Start date: August 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a one-arm, open, multicenter phase 1b/2 clinical trial of PE0116combined with PE0105 in patients with Advanced Solid Tumors, aiming at exploring the MTD and RP2D and observing the preliminary efficacy.The trial can be divided into two parts: dose escalation part and expansion part.PE0105 is administered as a fixed-dose intravenous injection(3mg/kg Q3w).